Home
Charts
Search
Watchlist
Products
All IPOs
₹139 - 139
Bio Medica Laboratories Ltd
PharmaceuticalsIPOSME
₹139 - 139
Our Company is engaged in the manufacturing of Pharmaceutical Parenteral Formulations. We manufacture generic drugs in the form of injectables namely Liquid Injections and Dry Powder Injections. These injectables are available in both single dose and multi dose forms, catering both human and veterinary needs. Our products address a wide range of medical needs and preferences.
Lot1,000Min Invest₹2,78,000Face Value₹10Issue Size₹52 CrFresh Issue₹47 CrOffer for Sale₹5 CrListing Price₹111CMP₹150
Timeline
21 May
Bidding opens
25 May
Bidding closes
26 May
Allotment
27 May
Refund & demat credit
28 May
Listing
Subscription
Subscription opens once dates are announced
Reports
Offer Details
Terms
Issue Size₹52 Cr0.38 Cr shares
Fresh Issue₹47 Cr
Offer for Sale₹5 Cr
Face Value₹10
Lot Size1,000 shares
ReservationQIB 1% · NII 48.98% · RETAIL 50.02%
Application Sizes
Retail₹2,78,0001-1 lots
sNII₹2,78,000from 2 lots
bNII₹11,12,000from 8 lots
Managers & Registrar
Lead ManagerNarnolia Financial Services Limited
RegistrarSkyline Financial Services Pvt
Ownership & Proceeds
Offer for Sale
Selling ShareholderShares OfferedAmt ₹ CrMukesh MehtaPRMTR1,88,5002.62Pradeep MehtaPRMTR1,88,5002.62Total3,77,0005.24
Shareholding
CategoryPre IPOPost IPOPromoter Group96.84%67.7%Public3.16%32.3%
Objects of the Issue
- Repayment of Loan
- Enhancement of its existing production capabilities by setting up of new manufacturing facility at the existing premises
- General Corporate Purposes*
- Offer for Sale (OFS)
Anchor Book
30-day lock-in24-Jun-202690-day lock-in23-Aug-2026
Financials
Profit & Loss
| Financial Year | FY25 | FY26 |
|---|---|---|
| RevenueCr | 38 | 43 |
| Operating ProfitCr | 15 | 20 |
| OPM% | 40.0 | 45.6 |
| PBTCr | 13 | 16 |
| PATCr | 10 | 12 |
| EPS | 11 | 13 |
Balance Sheet
| Financial Year | FY25 | FY26 |
|---|---|---|
| Equity CapitalCr | 9 | 9 |
| ReservesCr | 6 | 17 |
| BorrowingsCr | 15 | 40 |
| Total AssetsCr | 39 | 73 |
Cash Flow
| Financial Year | FY25 | FY26 |
|---|---|---|
| Operating Cash FlowCr | -5 | -6 |
| Investing Cash FlowCr | 0 | -2 |
| Financing Cash FlowCr | 5 | 8 |
| Net Cash FlowCr | 0 | 0 |
Strengths & Risks
Strengths · as stated in the DRHP
- Designing and execution capabilities.
- Experienced management team and a motivated and efficient work force.
- Cordial relations with our consumers.
- Quality assurance and control.
Strategies · as stated in the DRHP
- Expansion and upgradation of our manufacturing facility.
Risks · as stated in the DRHP
- The operations in the company Manufacturing Unit-1 had been suspended vide order No. V/T/MISC/20/2023/4790 dated August 23, 2023 by the Deputy Director and State Licensing Authority, Food and Drug Administration, Madhya Pradesh citing certain non-compliances.
- The company is dependent on a limited number of clients for a significant portion of its revenues, and the loss of any key client could adversely affect the company business, financial condition and results of operations.
- Any manufacturing or quality control problems may damage the company reputation for high quality products and expose its to litigation or other liabilities, which could adversely affect the company financial results.
- The Company's manufacturing facilities are subject to inspections by the Central Drugs Standard Control Organisation (CDSCO), the State Licensing Authorities, and other competent regulatory bodies. Any adverse findings or non-compliance may result in regulatory actions that could adversely affect the Company's business, operations, and financial performance
- The company is dependent on third-party transportation providers for the supply of raw materials and finished products
- The company inability to adopt new technologies could adversely affect its business, results of operations, cash flows and financial condition.